What's New with TAVR? An Update on Device Technology.
aortic stenosis
aortic valve replacement
prosthetic aortic valves
transcatheter aortic valve implantation
Journal
Methodist DeBakey cardiovascular journal
ISSN: 1947-6108
Titre abrégé: Methodist Debakey Cardiovasc J
Pays: United States
ID NLM: 101508600
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
03
2023
accepted:
15
03
2023
medline:
24
5
2023
pubmed:
22
5
2023
entrez:
22
5
2023
Statut:
epublish
Résumé
Over the last 20 years, transcatheter aortic valve replacement (TAVR) has revolutionized the management of aortic stenosis and has become the standard of care across the entire spectrum of surgical risk. Expansion of TAVR in treating younger, lower-risk patients with longer life expectancies, and treating earlier in the disease process, has seen a continuous evolution in device technology, with several next-generation transcatheter heart valves developed to minimize procedural complications and improve patient outcomes. This review provides an update on the latest advances in transcatheter delivery systems, devices, and leaflet technology.
Identifiants
pubmed: 37213874
doi: 10.14797/mdcvj.1230
pmc: PMC10198244
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4-14Informations de copyright
Copyright: © 2023 The Author(s).
Déclaration de conflit d'intérêts
Dr. Tang is a physician proctor for Medtronic, a consultant for Medtronic, Abbott, and NeoChord, a physician advisory board member for Abbott and JenaValve, and receives speakers honoraria from Siemens Healthineers and East End Medical. Dr. Kleiman is a local principal investigator in trials sponsored by Boston Scientific, Medtronic, Abbott, and Edwards Lifesciences. Dr. Reardon is a consultant for Medtronic, Boston Scientific, Abbott, and W. L. Gore & Associates. The other authors have no competing interests to declare.
Références
J Am Coll Cardiol. 2020 Nov 24;76(21):2492-2516
pubmed: 33213729
Can J Cardiol. 2017 Sep;33(9):1082-1090
pubmed: 28843322
EuroIntervention. 2014 Sep;10 Suppl U:U90-U100
pubmed: 25256338
Front Pediatr. 2020 Apr 24;8:198
pubmed: 32391296
JACC Cardiovasc Interv. 2022 Jun 13;15(11):1101-1110
pubmed: 35595675
Biomaterials. 2015 Jan;36:6-25
pubmed: 25443788
JACC Cardiovasc Interv. 2021 Dec 27;14(24):2754-2756
pubmed: 34949403
EuroIntervention. 2023 Mar 09;:
pubmed: 36895190
Circ Cardiovasc Interv. 2021 Sep;14(9):e010543
pubmed: 34433290
Am J Cardiol. 2023 Feb 15;189:1-10
pubmed: 36481373
JACC Cardiovasc Interv. 2023 Feb 27;16(4):498-500
pubmed: 36858671
Circulation. 2020 Dec 22;142(25):2431-2442
pubmed: 33054367
Circulation. 2021 Feb 2;143(5):e35-e71
pubmed: 33332149
Am J Cardiol. 2020 Apr 15;125(8):1222-1229
pubmed: 32093955
Lancet. 2019 Nov 2;394(10209):1619-1628
pubmed: 31570258
Eur Heart J. 2018 Jul 21;39(28):2625-2634
pubmed: 29718148
EuroIntervention. 2023 Apr 24;18(17):1418-1427
pubmed: 36880333
Eur J Cardiothorac Surg. 2011 Sep;40(3):761-3
pubmed: 21334914
JAMA. 2014 Jul;312(2):162-70
pubmed: 25005653
EuroIntervention. 2016 Sep 18;12(Y):Y22-7
pubmed: 27640026
J Heart Valve Dis. 2004 Sep;13(5):792-7
pubmed: 15473482
EuroIntervention. 2017 Dec 20;13(11):1296-1299
pubmed: 28846544
JACC Cardiovasc Interv. 2022 Apr 11;15(7):698-708
pubmed: 35393102
Ann Thorac Surg. 2005 Mar;79(3):1072-80
pubmed: 15734452
Nat Rev Cardiol. 2016 Jun;13(6):360-7
pubmed: 27053461
Ann Thorac Surg. 2022 Jan 20;:
pubmed: 35065065
J Am Coll Cardiol. 2004 Feb 18;43(4):698-703
pubmed: 14975485
J Clin Med. 2022 Mar 12;11(6):
pubmed: 35329887
Neth Heart J. 2015 Jan;23(1):35-41
pubmed: 25326104
J Am Coll Cardiol. 2017 Dec 5;70(22):2752-2763
pubmed: 29191323
J Thorac Cardiovasc Surg. 2014 Dec;148(6):3194-201
pubmed: 25218528
Heart Lung Circ. 2020 May;29(5):668-678
pubmed: 31839362
Cardiovasc Revasc Med. 2023 Feb;47:48-54
pubmed: 36266154
JACC Cardiovasc Interv. 2018 Aug 27;11(16):1663-1665
pubmed: 30139479
Circulation. 2002 Dec 10;106(24):3006-8
pubmed: 12473543